AMC IV, advised by Mezzanine Management, has exited its investment in Optimapharm d.d., a leading European Clinical Research Organisation (“CRO”), through a sale to The Rohatyn Group. The transaction generates a strong IRR and money multiple for investors in AMC IV following an 18-month partnership which saw profits triple as the business grew organically and through acquisitions.
AMC IV provided a €10 million mezzanine facility in October 2018 and acquired a minority equity stake in Optimapharm, marking the fund’s first investment into Croatia. Over the next 18 months, the capital was used to support organic expansion as well as three add-on acquisitions in the Czech Republic, Switzerland and Austria.